The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
#Bladder Cancer
#blcsm
#uroonc
Bacillus Calmette-Guérin
body mass index
diabetes mellitus
non-muscle-invasive bladder cancer
obesity paradox
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
pubmed:
20
11
2020
medline:
15
12
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
To evaluate if the obesity paradox, wherein obesity portends worse overall prognosis for a disease but improved outcomes for patients receiving immunotherapy, exists for patients receiving bacillus Calmette-Guérin (BCG) in a contemporary cohort. We performed an Institutional Review Board-approved database review to identify patients with non-muscle-invasive bladder cancer (NMIBC) completing at least an induction course of BCG. Clinicopathological variables collected included: body mass index (BMI), medications, and diabetes mellitus (DM). Outcomes of interest included: recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Univariate and multivariate modelling were used to evaluate the association between outcomes and clinical factors. A total of 579 patients (median follow-up 4.6 years) received BCG induction for NMIBC; 90% had high-grade disease (47.2% clinical stage T1). In all, 75.7% of patients were overweight or obese and 18% had DM. Aspirin, statins, metformin and β-blockers were used in 34%, 42%, 11%, and 29% of patients, respectively. Overweight and obese patients had improved PFS, CSS and OS. DM was associated with worse RFS. Medications of interest had no association with outcomes. Elevated BMI is associated with improved outcomes in patients with NMIBC treated with BCG immunotherapy. Patients with DM are at increased risk of recurrence. These findings support a potential obesity paradox in bladder cancer. Evaluation of the underlying mechanism and the role of global patient assessment, counselling, and risk factor modification are warranted.
Substances chimiques
Adjuvants, Immunologic
0
BCG Vaccine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-71Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International.
Références
Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One 2015; 10: e0119313
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-23
Bjørge T, Häggström C, Ghaderi S et al. BMI and weight changes and risk of obesity-related cancers: a pooled European cohort study. Int J Epidemiol 2019; 48: 1872-85
Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013; 104: 9-14
Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019; 15: 288
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine 2019; 47: 22-7
Marott SC, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Components of the metabolic syndrome and risk of type 2 diabetes. J Clin Endocrinol Metab 2016; 101: 3212-21
Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: an update. World J Urol 2020; 38: 1895-904
Kamat AM, Li R, O’Donnell MA et al. Predicting response to intravesical Bacillus Calmette-Guérin immunotherapy: are we there yet? A systematic review. Eur Urol 2018; 73: 738-48
Murphy WJ, Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA 2019; 321: 1247-8
Lennon H, Sperrin M, Badrick E, Renehan AG. The obesity paradox in cancer: a review. Curr Oncol Rep 2016; 18: 56
Ferro M, Vartolomei MD, Russo GI et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol 2019; 37: 507-14
Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials. Cancer Epidemiol Biomarkers Prev 2017; 26: 21-9
Zhang X, Zhang MJ, Fine J. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data. Stat Med 2011; 30: 1933-51
Westhoff E, Witjes JA, Fleshner NE et al. Body mass index, diet-related factors, and bladder cancer prognosis: a systematic review and meta-analysis. Bladder Cancer 2018; 4: 91-112
Ferro M, Vartolomei MD, Russo GI et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol 2019; 37: 507-14
Kluth LA, Xylinas E, Crivelli JJ et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 2013; 190: 480-6
Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials. Cancer Epidemiol Biomarkers Prev 2017; 26: 21-9
Hwang EC, Kim YJ, Hwang IS et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011; 18: 769-76
Rieken M, Xylinas E, Kluth L et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 2013; 112: 1105-12
Hu J, Chen JB, Cui Y et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine 2018; 97: e11596
Evers J, Grotenhuis AJ, Aben KK, Kiemeney LA, Vrieling A. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS One 2020; 15: e0229384
Xu T, Zhu Z, Wang X et al. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. Int Urol Nephrol 2015; 47: 1135-41
McQuade JL, Daniel CR, Hess KR et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 2018; 19: 310-22
Donnelly D, Bajaj S, Yu J et al. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J Immunother Cancer 2019; 7: 222
Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol 2017; 14: 85-99
Auyeung TW, Lee JS, Leung J, Kwok T, Leung PC, Woo J. Survival in older men may benefit from being slightly overweight and centrally obese-a 5-year follow-up study in 4,000 older adults using DXA. J Gerontol A Biol Sci Med Sci 2009; 65A: 99-104
Edwards BJ, Zhang X, Sun M et al. Overall survival in older patients with cancer. BMJ Support Palliat Care 2020; 10: 25-35
Zhang X, Tang T, Pang L et al. Malnutrition and overall survival in older adults with cancer: a systematic review and meta-analysis. J Geriatr Oncol 2019; 10: 874-83
Choi JB, Kim JH, Hong SH, Han KD, Ha US. Association of body mass index with bladder cancer risk in men depends on abdominal obesity. World J Urol 2019; 37: 2393-400